Ratings On Silgan Holdings Inc.'s Credit Facilities And Unsecured Notes Lowered; Recovery Ratings Revised Jul 10

  • ID: 2088676
  • July 2010
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) July 9, 2010--Standard & Poor's Ratings Services said today that it revised the ratings on Silgan Holdings Inc.'s senior secured credit facilities and senior unsecured notes following the completion of the company's new upsized credit facilities. The expanded borrowing capacity provides Silgan with greater flexibility with regard to its strategic initiatives, including the pursuit of acquisitions and share repurchases. However, the increase to the facility size by $350 million results in our expectation for reduced recovery in a default scenario, and lower recovery ratings. We lowered the issue-level ratings on the final $1.4 billion senior secured credit facilities to 'BBB-' (one notch above the 'BB+' corporate credit rating) from 'BBB', and we revised the recovery...

Companies mentioned in this report are: Silgan Holdings Inc.
Action: Downgraded

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

Silgan Holdings Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.